Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Genitourinary 1

Conditions

Stomach Neoplasms 2Breast Neoplasms 2Neoplasm Metastasis 1Cholangiocarcinoma 1Advanced and Metastatic Urothelial Cancer 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × futibatinib × Clear all
NCT04601857 2025-12-31

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Taiho Oncology, Inc.

Phase 2 Terminated
43 enrolled 15 charts
Genitourinary

Advanced and Metastatic Urothelial Cancer

NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Taiho Oncology, Inc.

Phase 2 Terminated
64 enrolled 21 charts
Breast

Breast Neoplasms

NCT04189445 2025-10-08

Futibatinib in Patients With Specific FGFR Aberrations

Taiho Oncology, Inc.

Phase 2 Terminated
115 enrolled 19 charts
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT02052778 2025-03-27

A Study of TAS-120 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed
407 enrolled 45 charts 1 FDA
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡